Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview.
The discovery of a second receptor for prostaglandin D2, chemoattractant receptor-homologous molecule expressed on T helper type 2 (CRTH2), has revived significant efforts into the development of small-molecule antagonists for allergic diseases as the receptor is predominantly expressed on cells such as eosinophils, TH2 cells and basophils, which are major pro-inflammatory cells in diseases such as asthma and allergic rhinitis. This brief review serves to illustrate current patent literature focusing on the similarities and differences of an ever-growing number of CRTH2 antagonists emerging from corporate laboratories.
Ly
Tai Wei
TW
Bacon
Kevin B
KB
D000818:Animals; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000502:physiology*; D011448:Prostaglandin Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000502:physiology*; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors* / Q000502:physiology*
D018836:Inflammation Mediators; D011448:Prostaglandin Antagonists; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; C036293:prostaglandin D2 receptor